CSI Market
Sign In | Register

Albireo Pharma inc (ALBO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALBO Annual Cash Flow →
Tracking cash flow results across Albireo Pharma inc to Sep 30 2021 helps illustrate how Sep 30 2022's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
9 Months 		(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Operating Activities
Income-120.18
Depreciation & amortization0.32
Amortization of Other Assets0.18
Accretion Expense8.25
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.10
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation10.67
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction7.62
Founders Compensation Contributed To Capital Adjustments-
Share Based Compensation For Non Employees-
Write Off Of Loan To Related Party-
Write Off Of Capitalized Patent Expense-
Loss On Settlement Of Convertible Loan-
Interest Expense Interest Bearing Liability0.40
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable1.02
Increase (Decrease) in Accounts Payable0.65
Increase (Decrease) in Accrued Liabilities-9.83
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense5.95
Other Working Capital-3.38
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-101.43
Investing Activities
Capital Expenditures-0.96
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Intangible Assets Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.96
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-10.80
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock26.88
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-248.11
Payments For Deferred Public Offering Costs-
Proceeds From Stockholder Contribution-
Proceeds From Bridge Financing-
Proceeds From Issuance Of Preferred Stock And Preference Stock One-
Net Proceeds From Atm Facility-
Fees Associated With Offering Cost-
Sale Of Stock Consideration Received Per Transaction-
Fees Associated Offering-
Net Expenses-
Proceeds From Royalty Agreement Net Of Transaction Expenses111.58
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents248.11
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities127.67
Effect of exchange rate on cash flow-0.91
Discontinued operations0.00
Free Cash Flow-102.39
Total Cash Flow24.37
4 historic quarters locked

Sign in to unlock the full Albireo Pharma inc cash flow history.

Sign In Create Free Account

About Albireo Pharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-22-016893

Figures are derived from filed reports and may be restated. Historical data is subject to revision.